DDX52 knockdown inhibits the growth of prostate cancer cells by regulating c-Myc signaling

Abstract

Background DDX52 is a type of DEAD/H box RNA helicase that was identified as a novel prostate cancer (PCa) genetic locus and possible causal gene in a European large-scale transcriptome-wide association study. However, the functions of DDX52 in PCa remain undetermined. The c-Myc oncogene plays a crucial role in the development of PCa, but the factors that regulate the activity of c-Myc in PCa are still unknown. Methods We determined DDX52 protein levels in PCa tissues using immunohistochemistry (IHC). DDX52 expression and survival outcomes in other PCa cohorts were examined using bioinformatics analysis. The inhibition of DDX52 via RNA interference with shRNA was used to clarify the effects of DDX52 on PCa cell growth in vitro and in vivo. Gene set enrichment analysis and RNA sequencing were used to explore the signaling regulated by DDX52 in PCa. Western blotting and IHC were used to determine the possible DDX52 signaling mechanism in PCa. Results DDX52 expression was upregulated in PCa tissues. Bioinformatics analysis showed that the level of DDX52 further increased in advanced PCa, with a high DDX52 level indicating a poor outcome. In vitro and in vivo experiments showed that downregulating DDX52 impeded the growth of PCa cells. High DDX52 levels contributed to activating c-Myc signaling in PCa patients and PCa cells. Furthermore, DDX52 expression was regulated by c-Myc and positively correlated with c-Myc expression in PCa. Conclusion DDX52 was overexpressed in PCa tissues in contrast to normal prostate tissues. DDX52 knockdown repressed the growth of PCa cells in vitro and in vivo. Deleting c-Myc inhibited DDX52 expression, which affected the activation of c-Myc signaling.

Landscape of RNA-binding proteins in diagnostic utility, immune cell infiltration and PANoptosis features of heart failure

“…Further, a characteristic gene-based nomogram was established, which was capable of accurately predicting heart failure risk, with the excellent clinical usability. DDX52 is a type of DEAD/H box RNA helicase, and its suppression exerts an anti-tumor effect (Yu et al, 2021). The DEAH-box RNA helicase DHX15 has been identified as a potential gene for pathological cardiac hypertrophy triggered by excessive exercise (Zhou et al, 2020) and pulmonary arterial hypertension (Wang et al, 2021).…”

Overexpression of DDX49 in prostate cancer is associated with poor prognosis

“…In another study, DDX3 also regulated AR posttranscriptionally by sequestering mRNA, and inhibiting DDX3 was sufficient to reduce AR protein expression and signalling, resensitizing PCa cells to AR signalling inhibitors [ 16 ]. Yu et al [ 17 ] reported that DDX52 knockdown inhibits PCa cell growth by regulating c-Myc signal transduction, and they found that DDX52 has a significant decreasing effect on c-Myc, which promotes the progression of PCa and that c-Myc’s oncogenic potential in PCa cells may rely on DDX52. However, the DDX family comprises at least 35 genes, most of which have not been evaluated for function in PCa, especially in castration-resistant PCa.…”

DDX52 gene expression in LUAD tissues indicates potential as a prognostic biomarker and therapeutic target

“…Its significance extends from its contribution to the onset and progression of various human ailments. For instance, studies on prostate cancer cells suggest that DDX52 inhibition can effectively retard cancer cell growth by modulating the c-Myc signaling pathway 8 . Findings from a zebrafish model emphasize DDX52’s role as a growth regulator during early developmental stages 9 .…”